Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Dana Chase

Gyn Onc · UCLA

View

Dr. Kimberly Resnick

Gyn Onc · MetroHealth

View

Dr. Ashley Stuckey

Gyn Onc · Women & Infants Hospital

View

Dr. Susan Khalil

MIGS · ISMMS

View

Dr. Tori O’Daniel

OB Hospitalist · Laborie-MCH division, Senior Medical Director

View

Dr. Alissa Erogbogbo

OB Hospitalist · Washington Health System

View

Dr. Christina Adams

OB Hospitalist · Flagler Hospital

View

Dr. Brigid McCue

OB Hospitalist · Northwell Health

View

Dr. Bruce Bekkar

General OBGYN · ecoAmerica

View

Dr. Jennifer Lincoln

OB Hospitalist · Providence

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Validation of the Safety and Efficacy of Apixaban as Postoperative Thromboembolism Prophylaxis for Patients with Gynecologic Malignancies.

    May 23, 2024DOI: 10.1245/s10434-024-15369-8Journal ArticleASO

    Written by: Jessica FloydHector Porragas-PaseiroCam NguyenMarisa R MoroneySpyridon MastroyannisSaketh R Guntupalli

    Find these authors on Roon

    SM
    Dr. Spyridon Mastroyannis
    Gyn Onc · University of Colorado

    Summary

    BACKGROUND: Venous thromboembolism is a preventable complication of gynecologic cancer surgery that leads to postoperative morbidity and mortality. This study compared apixaban with enoxaparin to identify whether apixaban had the same safety and efficacy for patients undergoing gynecologic cancer surgery.METHODS: The study identified patients with a gynecologic malignancy who underwent surgery and were prescribed apixaban at discharge between June 2020 and April 2023. International Classification of Diseases 10 codes were used to identify patients who had a thromboembolism within 90 days or a bleeding event within 60 days after surgery. The rates of events for patients prescribed apixaban were compared with those for a historical cohort of patients who received enoxaparin. Fisher's exact tests were used to compare categorical variables, and t tests were used to compare continuous variables. A logistic regression was performed to compare the odds of thromboembolism between the two groups.RESULTS: Baseline patient characteristics differed in terms of body mass index (BMI), race, route of surgery, and type of cancer. Of the 490 patients in the apixaban cohort, 12 (2.4%) had a thromboembolism compared with 3 (2.1%) of the 138 patients in the enoxaparin group (adjusted odds ratio [aOR], 1.02; 95% confidence interval [CI] 0.30-4.70; p > 0.999). The odds ratio was adjusted for BMI, age, and route of surgery. A bleeding event occurred for 1 (0.2%) of the 490 patients in the apixaban group and for 1 (0.7%) of the 138 patients in the enoxaparin group.CONCLUSIONS: This validation study showed that apixaban is a safe and effective method of postoperative venous thromboembolism prophylaxis. The data provide support to previous data and guideline updates recommending the use of apixaban for postoperative prophylaxis.
    SMDr. Spyridon Mastroyannis

    Dr. Spyridon Mastroyannis

    Obstetrics & Gynecology (OBGYN) · Gynecologic Oncology
    University of Colorado Health
    spyridon